Document Type


Publication Date

Fall 11-18-2020


Cancer treatments are shifting from heavy adjuvant therapies to immunological approaches, such as carT cell therapy. By simultaneously administering two known successful treatments for ALL, Blinatumomab and Kymriah, a high rate of remission can be accomplished in pediatric patients with relapsed ALL. Higher rates of remission, prolonged immunity, and less side effects are the projected results based on previously published studies. Combining these two therapies will likely produce more successful results compared to if the drugs were administered independently. This will hopefully translate into a faster return to daily living activities and less chronic effects during such an important developmental period of a child's life.


BIOL 488

Streaming Media

Included in

Biology Commons



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.